EUVIMEDEUVIMED entdecken
Crossref

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data

A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina

Pediatric pharmacology · 2016

DOI: 10.15690/pf.v13i4.1606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric pharmacology, 2016. Verfasst von A. S. Kolbin und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.

Objective

Our aim was to evaluate the clinical and economic expediency of using omalizumab as additive treatment (to basic or supporting therapy) in children with severe uncontrolled atopic asthma under the Russian economic conditions.

Methods

We conducted a mathematical simulation of asthma treatment in children with an increased frequency of hospitalization (9 times per year) with an average monthly omalizumab requirement of 558 mg. The model is based on the Markov chain. The model includes direct and non-direct costs. The planning horizons were 2 and 5 years. We analyzed the efficiency and utility of the costs and their influence on the budget. The stability of received data is proven by sensitivity analyzis.

Results

Over a 5-year planning horizon the cost of an additional year of quality life (due to using omalizumab) was 1,259,185 roubles, while the “society’s solvency” is 1 341 308 roubles (cost utility analizis). It takes 39,820 rubles to prevent one hospitalization with omalizumab over a 5-year planning horizon (cost efficiency analizis), which is comparable to the cost of hospitalization (43,141 rubles). Total costs for treating 100 children with asthma, 7 of which would be treated with omalizumab, were equal to the amount of money which is enough to treat 105 children without omalizumab (analysis of budgetary influence).

Conclusion

The analyses of cost efficiency and utility have shown that the strategy of using omalizumab together with standard treatment is economically expedient. Budgetary influence analysis has not detected a significant burden on the budget.

Zitieren

APA

Kolbin, A. S., Namazova-Baranova, L. S., Vishneva, E. A., Frolov, M. Y., Galankin, T. L., Alekseeva, A. A., & Dobrynina, E. A. (2016). A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data. Pediatric pharmacology. https://doi.org/10.15690/pf.v13i4.1606

Vancouver

Kolbin AS, Namazova-Baranova LS, Vishneva EA, Frolov MY, Galankin TL, Alekseeva AA, et al. A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data. Pediatric pharmacology. 2016. doi:10.15690/pf.v13i4.1606

BibTeX
@article{Kolbin2016,
  author = {Kolbin, A. S. and Namazova-Baranova, L. S. and Vishneva, E. A. and Frolov, M. Y. and Galankin, T. L. and Alekseeva, A. A. and Dobrynina, E. A.},
  title = {A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data},
  journal = {Pediatric pharmacology},
  year = {2016},
  doi = {10.15690/pf.v13i4.1606}
}
Kostenlos starten →